Loading...
A two-part phase II study of cediranib in patients with advanced solid tumours: the effect of food on single-dose pharmacokinetics and an evaluation of safety, efficacy and imaging pharmacodynamics.
Mitchell, Claire L O'Connor, James P B Roberts, C Watson, Y Jackson, A Cheung, S Evans, J Spicer, J Harris, A Kelly, C
Mitchell, Claire L
O'Connor, James P B
Roberts, C
Watson, Y
Jackson, A
Cheung, S
Evans, J
Spicer, J
Harris, A
Kelly, C
Citations
Altmetric:
Abstract
Cediranib (RECENTIN™) is an oral, highly potent VEGF inhibitor. This study evaluated the effect of food on the pharmacokinetics of cediranib and compared the administration of continual cediranib via two dosing strategies using this as a platform to investigate pharmacodynamic imaging biomarkers.
Description
Date
2011-09
Publisher
Collections
Files
Loading...
CORE by link
Adobe PDF, 543.37 KB
Keywords
Type
Article
Citation
A two-part phase II study of cediranib in patients with advanced solid tumours: the effect of food on single-dose pharmacokinetics and an evaluation of safety, efficacy and imaging pharmacodynamics. 2011, 68 (3):631-41 Cancer Chemother Pharmacol